What is the recommended treatment for an adult with a flare of plaque psoriasis?

Treatment of Plaque Psoriasis Flare in Adults

For an adult experiencing a flare of plaque psoriasis, initiate treatment based on disease severity: topical corticosteroids (ultrahigh potency class 1) combined with calcipotriene for localized disease, or systemic therapy with methotrexate for moderate-to-severe disease requiring rapid control, with biologics (anti-IL17 or anti-IL23 agents) reserved for inadequate response or when systemic therapy is indicated from the outset. 1

Treatment Algorithm by Disease Severity

Mild to Moderate Psoriasis (Localized Flare)

• Start with ultrahigh potency (class 1) topical corticosteroids as first-line therapy for rapid symptom control 1
• Add calcipotriene to the topical corticosteroid regimen to enhance efficacy and potentially reduce steroid exposure 1
• Consider combination calcipotriene/betamethasone formulations for convenience and improved adherence 1

Moderate to Severe Psoriasis (>10% BSA or High-Impact Areas)

First-line systemic options:

• Methotrexate 7.5-25 mg weekly is recommended as the primary conventional systemic agent for moderate-to-severe psoriasis, particularly effective for achieving disease control during flares 1

  • Administer orally or subcutaneously; subcutaneous route may improve bioavailability 1
  • Always co-prescribe folic acid or folinic acid to reduce gastrointestinal and hepatic adverse effects (though large doses may reduce methotrexate efficacy) 1
  • Consider a test dose in patients with impaired kidney function 1
  • Monitor liver function tests every 3-6 months 1

• Cyclosporine is recommended for short-term control of acute flares when rapid disease suppression is needed 2

Biologic Therapy Considerations

When systemic therapy is indicated or conventional agents fail:

Most effective biologics for achieving PASI 90 (in rank order):

1. Infliximab (moderate-certainty evidence) 3
2. Bimekizumab (anti-IL17, high-certainty evidence) 3
3. Ixekizumab (anti-IL17, moderate-certainty evidence) 3
4. Risankizumab (anti-IL23, moderate-certainty evidence) 3

• Anti-IL17 agents as a class demonstrate superior efficacy compared to all other intervention classes for achieving clear or almost clear skin 3
• Anti-IL17 and anti-IL23 biologics show evidence of superiority over anti-TNF agents (adalimumab, etanercept, certolizumab) and ustekinumab 3
• Methotrexate is less effective than adalimumab and infliximab for cutaneous psoriasis 1

Combination Therapy Strategies

When using biologics with persistent lesions:

• Adding ultrahigh potency (class 1) topical corticosteroid to etanercept for 12 weeks is recommended (strength A recommendation) 1
• Adding calcipotriene/betamethasone to adalimumab for 16 weeks accelerates clearance of psoriatic plaques (strength B recommendation) 1
• All topical corticosteroids can be combined with any biologic for moderate-to-severe psoriasis 1

When using methotrexate:

• Adding topical calcipotriene to standard-dose methotrexate is recommended (strength A recommendation, level I evidence) 1
• Combination with narrowband UVB phototherapy can be considered to enhance efficacy and lower cumulative doses of both treatments 1

Novel Oral Targeted Therapy

• Icotrokinra (oral IL-23 receptor inhibitor) represents a promising alternative for patients reluctant to use injectable biologics, demonstrating 65% IGA 0/1 response and 50% PASI 90 response at week 16 versus 8% and 4% with placebo 4
• This first-in-class oral peptide shows efficacy comparable to injectable biologics with favorable safety profile 5, 4

Critical Safety Considerations

Methotrexate contraindications and monitoring:

• Absolutely contraindicated in pregnancy, cirrhosis, significant cytopenias, and while nursing 1
• Women of childbearing age must use contraception; wait at least 3 months after discontinuation before attempting pregnancy 1
• Avoid moderate alcohol use (>1 drink/day for women, >2 drinks/day for men) 1
• Baseline and annual hepatotoxicity monitoring with noninvasive hepatic serology in patients with risk factors 1

Biologic safety:

• No evidence of difference between biologics and placebo for serious adverse events, though this is based on low-certainty evidence with few events 3
• Most common adverse events across biologics include nasopharyngitis and upper respiratory tract infections 4

Common Pitfalls to Avoid

• Do not use methotrexate without concurrent folic/folinic acid supplementation 1
• Do not continue methotrexate in patients with persistent liver function test elevations without gastroenterology referral 1
• Avoid underdosing methotrexate; therapeutic range is 7.5-25 mg weekly, not the minimal dose 1
• Do not delay escalation to biologics in patients with inadequate response to conventional systemics, as anti-IL17 and anti-IL23 agents demonstrate significantly superior efficacy 3